FDA Compliance Policy Guides Manual Signals Enforcement Priorities for Drug Plant Inspections

For plant heads and QA directors preparing for the next inspection cycle, FDA's Compliance Policy Guides (CPG) manual remains one of the most underutilized pre-inspection resources available, a structured window into how agency staff are instructed to assess and enforce industry compliance before an investigator sets foot on the floor.

CPGs are internal FDA documents that establish agency policy and interpretive positions where existing statutes, regulations, or guidance leave gaps. They are not regulations, but they carry operational weight: FDA investigators reference them when determining enforcement strategy, which means a facility's compliance posture should account for any CPG relevant to its product category and manufacturing operations.

The manual is organized into six subject-matter chapters: General, Biologics, Devices, Human Drugs, Food/Colors/Cosmetics, and Veterinary Medicine. For most drug manufacturers operating under 21 CFR Part 211, the Human Drugs chapter warrants the closest read, though the General chapter, administered by the Division of Inspectorate Policy (DIP) within the Office of Inspectional Performance Optimization, sets cross-cutting interpretive standards that apply regardless of product type.

QA directors tracking emerging enforcement signals should note that CPGs are revised periodically. FDA staff who identify a need for a new or updated CPG are directed to contact the relevant FDA Center, with DIP serving as the coordinating body for General chapter inquiries. Monitoring the CPG manual for additions or revisions between inspection cycles is a practical method for anticipating where agency scrutiny may sharpen, particularly in areas where existing guidance is silent or ambiguous.

The manual is publicly accessible via FDA's inspections and compliance portal, alongside the agency's broader guidance document library and SMG 7100.1, which governs management of the CPG manual itself. Cross-referencing CPG positions with a facility's current CAPA inventory and internal audit findings is a defensible way to close interpretive gaps before they surface during an inspection.

Facilities that align their compliance programs with CPG positions, not just codified regulations, are better positioned to demonstrate the kind of proactive quality culture that ICH Q10 describes as a prerequisite for sustained GMP performance.

Source: FDA Inspections, Compliance, Enforcement, and Criminal Investigations portal via FDA.gov What's New: Drugs RSS Feed, 27 October 2026.